Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BRCA1, PARP, and 53BP1: conditional synthetic lethality and synthetic viability

30 Jan 2011

Abstract excerpt

BRCA1 plays a critical role in the regulation of homologous recombination (HR)-mediated DNA double-strand break repair. BRCA1-deficient cancers have evolved to tolerate loss of BRCA1 function. This renders them vulnerable to agents, such as PARP inhibitors, that are conditionally 'synthetic lethal' with their underlying repair defect. Recent studies demonstrate that BRCA1-deficient cells may acquire resistance to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CRISPR and Genetic Engineering
Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 21278454
DOI: 10.1093/jmcb/mjq055

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BRCA1, PARP, and 53BP1: conditional synthetic lethality and synthetic viabilityPMID 21278454Read ↗

BRCAness, DNA gaps, and gain and loss of PARP inhibitor–induced synthetic lethalitySemantic proximity Read ↗

Mechanisms of PARP1 inhibitor resistance and their implications for cancer treatmentSemantic proximity Read ↗

Breast Cancer Predisposition Genes and Synthetic Lethality.Semantic proximity Read ↗

Mechanisms of resistance to therapies targeting BRCA-mutant cancers.Semantic proximity Read ↗

RAD52 as a Potential Target for Synthetic Lethality-Based Anticancer TherapiesSemantic proximity Read ↗

Synthetic lethality: exploiting the addiction of cancer to DNA repair.Semantic proximity Read ↗

PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedsideSemantic proximity Read ↗

Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors.Semantic proximity Read ↗

BRCA1 and BRCA2: from cancer susceptibility to synthetic lethality.Semantic proximity Read ↗

Therapeutic intervention by the simultaneous inhibition of DNA repair and type I or type II DNA topoisomerases: one strategy, many outcomes.Semantic proximity Read ↗

Drugging the Cancers Addicted to DNA RepairSemantic proximity Read ↗

Embracing synthetic lethality of novel anticancer therapies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.